Deliverance Acceptance Criteria Sample Clauses

Deliverance Acceptance Criteria. Sprint Acceptance of the Deliverables and Services is based on Service Provider delivery in accordance with attached Sprint Specifications included in Exhibits A (Software Product Specifications), Exhibit B (Hosting Services Specifications), and Exhibit E (Software Product and Services Improvement Roadmap). For the avoidance of doubt, Sprint’s certification of a Device by STIC is acceptance of the Software Product for that Device and completion of the Hosting Services in accordance with the Hosting Services Service Level Agreement and Exhibit B [Hosting Services Specifications] constitutes acceptance of such Service. If Sprint determines that a Deliverable or the Software Product does not conform with the Sprint Specifications listed above and notifies Service Provider, including with such notice an exception report describing the nonconformity (the “Exception Report”), Service Provider will promptly investigate the alleged nonconformity and will take commercially reasonable efforts to correct such nonconformity upon receipt of the Exception Report. Upon Service Provider’s notice to Sprint that Service Provider has cured such nonconformity, Sprint will re-test the defective component or deliverable as provided in this Section 12.1 [Deliverance Acceptance Criteria]. In the event that, despite the exercise of commercially reasonable efforts, Service Provider is unable to make the applicable Software Product technically compatible with a Device that Sprint has requested, the parties shall work together to attempt to find a solution. If the parties are unable to jointly find any solution despite the exercise of commercially reasonable efforts, then the parties may mutually agree that the applicable Software Product shall not be loaded on such Device. In the instance that Service Provider is not able to make the Software Product conforming for at least [*] of all Devices specified by Sprint in Section 4.4 [Service Provide Device Obligations], other than those that the parties mutually agree shall not have the Software Product loaded, as set forth in the prior paragraph, Sprint may terminate this Fourteenth Amendment for cause subject to the cure period as set forth in Section 3.2.1 [Sprint Termination for Cause]. For the avoidance of doubt, [*] of all Devices shall be calculated as the aggregate quantity of individual Devices and not the number of SKUs or models.
AutoNDA by SimpleDocs

Related to Deliverance Acceptance Criteria

  • Acceptance Criteria a) The operational ground check, the engine performance check and the acceptance flight contemplated in clause 2.2, 2.3 and 2.4 shall be conducted using Airbus’ ISATM.

  • Performance Criteria The Performance Criteria are set forth in Exhibit A to this Agreement.

  • Purge Criteria In order to avoid the Aged History Retention fees, history data for regular or ordinary accounts (that is, non-tax advantaged accounts) must be purged if the confirmation date of the history transaction is prior to January 1 of the current year and history data for tax advantaged accounts (retirement and educational savings accounts) must be purged if the confirmation date of the history transaction is prior to January 1 of the prior year. All purged history information shall be retained on magnetic tape for 7 years.

  • Commercial Milestones In partial consideration of the rights granted by AstraZeneca to Licensee hereunder, Licensee shall pay to AstraZeneca the following payments, which shall be non-refundable, non-creditable and fully earned upon the first achievement of the applicable milestone event:

  • Equity Award Acceleration All outstanding equity awards held by the Executive on the Date of Termination shall immediately become fully vested and, to the extent applicable, exercisable. For the avoidance of doubt, all such equity awards shall remain outstanding and eligible to vest following the Date of Termination and shall actually vest and become exercisable (if applicable) and non-forfeitable upon the effectiveness of the Release.

  • Performance Goals A. The Trust and State Street have developed mutually acceptable performance goals dated March 1, 2011 , and as may be amended from time to time, regarding the manner in which they expect to deliver and receive the services under this Agreement (hereinafter referred to as “Service Level Agreement”). The parties agree that such Service Level Agreement reflects performance goals and any failure to perform in accordance with the provisions thereof shall not be considered a breach of contract that gives rise to contractual or other remedies. It is the intention of the parties that the sole remedy for failure to perform in accordance with the provisions of the Service Level Agreement, or any dispute relating to performance goals set forth in the Service Level Agreement, will be a meeting of the parties to resolve the failure pursuant to the consultation procedure described in Sections V. B. and V.C. below. Notwithstanding the foregoing, the parties hereby acknowledge that any party’s failure (or lack thereof) to meet the provisions of the Service Level Agreement, while not in and of itself a breach of contract giving rise to contractual or other remedies, may factor into the Trust’s reasonably determined belief regarding the standard of care exercised by State Street hereunder.

  • Committee Discretion to Accelerate Vesting Notwithstanding the foregoing, the Committee may, in its sole discretion, provide for accelerated vesting of the Option at any time and for any reason.

  • Severance and Change in Control Benefits The Committee has designated you a participant in the Company’s Executive Change in Control and Severance Plan (the “Policy”), attached as Exhibit A to this Agreement. As a participant in the Policy, you will be eligible to receive severance payments and benefits upon certain qualifying terminations of your Employment as set forth in Exhibit B to this Agreement (the “Participation Terms”), subject to the terms and conditions of the Policy. By signing this Agreement, you agree that this Agreement, the Policy, and the Participation Terms constitute the entire agreement between you and the Company regarding the subject matter of this paragraph and supersede in their entirety all prior representations, understandings, undertakings or agreements (whether oral or written and whether expressed or implied), and specifically supersede any severance and/or change of control provisions of any offer letter, employment agreement, or equity award agreement entered into between you and the Company. For the avoidance of doubt, all other terms of any equity awards granted to you by the Company will remain in effect.

  • Sales Milestones As to each of the sales milestone events set forth below, GSK shall pay EPIZYME the non-refundable, non-creditable sales milestone payments indicated below upon the first achievement by GSK, its Affiliates or Sublicensees of the success milestone events set forth below with respect to each Selected Target, on a Selected Target-by-Selected Target basis. Sales Milestone Event (For Licensed Products directed to a Selected Target) Milestone Payment (in $ [**]) First Calendar Year in which aggregate world-wide Net Sales of Licensed Product(s) directed to such Selected Target are greater than or equal to $[**] [** ] First Calendar Year in which aggregate world-wide Net Sales of Licensed Product(s) directed to such Selected Target are greater than or equal to $[**] [** ] First Calendar Year in which aggregate world-wide Net Sales of Licensed Product(s) directed to such Selected Target are greater than or equal to $[**] [** ] Upon achievement by or on behalf of GSK, its Affiliates or Sublicensees of a sales milestone event set forth in this Section 6.7, GSK shall promptly (but in no event later than the date on which the royalty report for the Calendar Quarter in which such achievement occurs is due pursuant to Section 6.10.1) notify EPIZYME of such achievement, and GSK shall pay EPIZYME the corresponding sales milestone payment within [**] days after receipt of an invoice for the milestone payment from EPIZYME. Such invoice shall be sent to GSK’s Alliance Manager and [**] with a copy to [**] (or such other email address(es) as may be notified to EPIZYME by GSK). For the avoidance of doubt, more than one of the foregoing sales milestone payments may be earned and become payable with respect to Licensed Products directed to any given Selected Target in the same Calendar Year based on aggregate world-wide Net Sales of Licensed Product(s) directed to such Selected Target during such Calendar Year.

  • Change in Control Benefit If a Change in Control occurs followed within twenty-four (24) months by Separation from Service prior to Normal Retirement Age, the Bank shall distribute to the Executive the benefit described in this Section 2.4 in lieu of any other benefit under this Article.

Time is Money Join Law Insider Premium to draft better contracts faster.